Efficacy and Safety of 0.5% w/v Nano- Silver Nitrate Versus Silver Nitrate Solution for Bronchoscopic Lung Volume Reduction in Management of Localized Emphysema: Prospective Interventional Randomized Controlled Clinical Trial

Emphysema is a progressive phenotype of chronic Obstructive Pulmonary Disease (COPD), poses a significant global health burden characterized by irreversible lung parenchymal destruction and airspace enlargement.
In recent years, bronchoscopic lung volume reduction (BLVR) has considerable interest as a minimally invasive approach to reducing hyperinflation and improving lung function in patients with emphysema.
BLVR techniques aim to achieve lung volume reduction by occluding or ablating emphysematous lung tissue through endobronchial delivery of various agents. Many techniques are available for BLVR as coil, endo-bronchial valve, and biological as thrombin, autologous blood and chemicals as silver nitrate solution.

Start Date01 Oct 2024

Sponsor / Collaborator

Mansoura University Hospital

CTRI/2024/06/068709 / Not yet recruitingNot ApplicableIIT

Indirect Pulp Treatment In Young Permanent Molars: 38% Silver Diamine Fluoride (SDF) with and without light cure- A Clinical Control Trial - NIL

Start Date22 Jun 2024

Sponsor / Collaborator-

CTRI/2024/05/068228 / Not yet recruitingPhase 4IIT

A study comparing the efficacy of tertiary ammonium compound based foam dressing versus silver based foam dressing in non ischemic diabetic foot ulcer patients using wound ischemia foot infection grading WIFI GRADE 2 in a tertiary care hospital - NIL

Start Date12 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Silver Nitrate

100 Translational Medicine associated with Silver Nitrate

100 Patents (Medical) associated with Silver Nitrate

4,045

Literatures (Medical) associated with Silver Nitrate

01 Mar 2025·Journal of Orthopaedics

Comparative effectiveness of silver-coated implants in periprosthetic infection prevention: A systematic review and meta-analysis

Review

Author: Bulut, Halil Ibrahim ; Kanay, Enes ; Okay, Erhan ; Ozkan, Korhan ; Batibay, Sefa Giray

Introduction:

Despite the implementation of numerous preventive measures in recent years, the persistent challenge of periprosthetic infections remains. Among the various strategies, metallic modification of implants, particularly with silver, has emerged as a promising avenue. Silver's antimicrobial properties, coupled with its low human toxicity, render it an appealing option. However, ongoing debate surrounds its comparative efficacy in infection prevention when contrasted with titanium-coated prostheses.

Methods:

The PubMed database was systematically searched up to March 2024. Studies in English that met predetermined inclusion/exclusion criteria and utilized "Megaprosthesis AND infection" and " silver-coated AND infection " as key terms were included. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guided the article selection process.

Results:

From a pool of 1892 potential papers after literature screening, 11 studies with a total of 1419 patients were meticulously selected for analysis. Among these patients, 638 were treated with silver-coated implants, while 781 received titanium-coated implants, resulting in 166 recorded cases of infection. Remarkably, the infection rate stood at 9.2 % for the silver-coated group, contrasting with 13.4 % for the titanium-coated group. The subsequent analysis unveiled a notable discrepancy in proportions (P difference = -0.0473, 95 % CI: -0.088 to -0.006), signaling a statistically significant decrease in infections within the silver-coated cohort. Furthermore, the I2 statistic, denoting heterogeneity in effect sizes, stood at 21.8 % (95 % CI: 0.0-66.9), indicating a modest degree of variability among the studies. These findings offer compelling insights into the comparative effectiveness of silver-coated implants, suggesting their potential superiority in infection prevention.

Conclusion:

In conclusion, our systematic review and meta-analysis shed light on the potential of silver-coated implants in mitigating periprosthetic infections. Despite the persistent challenge posed by such infections, our findings suggest a statistically significant decrease in infection rates among patients treated with silver-coated implants compared to those with titanium-coated ones.

01 Jan 2025·JOURNAL OF HOSPITAL INFECTION

Povidone-iodine and silver nitrate are equally effective in eradicating staphylococcal biofilm grown on a titanium surface: an in-vitro analysis

Article

Author: Huespe, Iván ; Semeshchenko, Daniyil ; Slullitel, Pablo A. ; Veiga, Maria F ; Farinati, Alicia ; Lucero, Carlos M. ; Comba, Fernando ; Slullitel, Pablo A ; Veiga, Maria F. ; Buttaro, Martin A ; Zanotti, Gerardo ; Albani-Forneris, Agustín F. ; Visus, Mariangeles ; Buttaro, Martin A.

BACKGROUND:

There is no consensus on the irrigation solution and concentration that should be used when performing a debridement, antibiotics, and implant retention (DAIR)-surgery.

AIM:

To determine the minimum-biofilm-eradication-concentration of five antibacterial solutions and compare their efficacy in eradicating Staphylococcal biofilm embedded on a titanium surface.

METHODS:

Methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) ATCC standard strains were grown over porous Ti-6Al-4V acetabular screw-caps. Antibacterial solutions were povidone iodine, rifampicin, silver nitrate, copper sulphate, chlorhexidine. Minimum biofilm eradication concentration (MBEC) values were calculated for MSSA and MRSA. After 24 hours, screw-caps were exposed 3 minutes to each solution. Bacterial separation from each specimen was performed with vortex agitation and footprint on agar plate in triplicate. Colony forming units (CFU) were counted pre- and post-agitation, and the delta of CFU/ml was calculated for each solution. A three-fold log reduction in CFU was considered a measure of solution efficacy. Comparison between groups was made with Fisher's test.

FINDINGS:

MBEC values for MSSA and MRSA, respectively, were as follows: 8000 ug/mL and 16000 ug/ml for povidone iodine; 64 ug/mL and 128 ug/mL for rifampicin; 10000 ug/mL and 5120 ug/mL for silver nitrate; 900 ug/mL and 900 ug/mL for copper sulphate; 16 ug/mL and 32 ug/mL for chlorhexidine. Rifampicin, copper sulphate and chlorhexidine were ineffective against MSSA and MRSA biofilm compared to povidone iodine (p<0.01) and silver nitrate (p=0.015) that had a delta CFU reduction >8 log. Povidone iodine and silver nitrate showed negative footprints without visible MSSA (p=0.005) and MRSA (p=0.014).

CONCLUSIONS:

Povidone iodine and silver nitrate were the only irrigating solutions capable of eradicating at least 99.9% of 24-hour biofilm.

31 Dec 2024·Artificial cells, nanomedicine, and biotechnology

Synthesis and characterization of Fe ₃ O ₄ @SiO ₂ @PDA@Ag core–shell nanoparticles and biological application on human lung cancer cell line and antibacterial strains

Article

Author: Singh, Aarushi ; Chugh, Heerak ; Chandra, Ramesh ; Singh, Snigdha ; Roy, Indrajit ; Chakraborty, Nayanika ; Tiwari, Manisha ; Goel, Tanya

Novel magnetic and metallic nanoparticles garner much attention of researchers due to their biological, chemical and catalytic properties in many chemical reactions. In this study, we have successfully prepared a core-shell Fe₃O₄@SiO₂@PDA nanocomposite wrapped with Ag using a simple synthesis method, characterised and tested on small cell lung cancer and antibacterial strains. Incorporating Ag in Fe₃O₄@SiO₂@PDA provides promising advantages in biomedical applications. The magnetic Fe₃O₄ nanoparticles were coated with SiO₂ to obtain negatively charged surface which is then coated with polydopamine (PDA). Then silver nanoparticles were assembled on Fe₃O₄@SiO₂@PDA surface, which results in the formation core-shell nanocomposite. The synthesised nanocomposite were characterized using SEM-EDAX, dynamic light scattering, XRD, FT-IR and TEM. In this work, we report the anticancer activity of silver nanoparticles against H1299 lung cancer cell line using MTT assay. The cytotoxicity data revealed that the IC₅₀ of Fe₃O₄@SiO₂@PDA@Ag against H1299 lung cancer nanocomposites cells was 21.52 µg/mL. Furthermore, the biological data of nanocomposites against Gram-negative 'Pseudomonas aeruginosa' and Gram-positive 'Staphylococcus aureus' were carried out. The range of minimum inhibitory concentration was found to be 115 µg/mL where gentamicin was used as a standard drug. The synthesized AgNPs proves its supremacy as an efficient biomedical agent and AgNPs may act as potential beneficial molecule in lung cancer chemoprevention and antibacterial strains.

News (Medical) associated with Silver Nitrate

16 Apr 2024

·www.prnewswire.com

Journal of the American Chemical Society Differentiates EVŌQ Nano's EVQ-218 Nanoparticle as a New Form of Silver; Holds Promise for Widespread Medical Applications

EVQ-218 is the first stable, nonemissive, pure metal nanoparticle on par with NIST standards for ideal materials. The 'clean and green' EVQ-218 nanosilver is free of toxic ion emissions. SALT LAKE CITY, April 16, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, materials, and textile science industries, today announced that the American Chemical Society journal, ACS Omega, published a peer-reviewed study characterizing and differentiating the company's lead asset, EVQ-218, as a new form of silver nanoparticle (AgNP). EVQ-218 meets the highest standards set by the National Institute of Standards and Technology (NIST) while avoiding the limitations and safety risks of other nanosilvers. Continue Reading Engineered by EVŌQ Nano, EVQ-218 is the first and only stable, non-ionic silver nanoparticle (AgNP) for medical applications. The characterization of EVQ-218 is timely as the rise of antimicrobial resistance (AMR) has caused a surge of research into safer, more effective treatments. Prioritized by the World Health Organization as one of the top 10 global public health threats, AMR threatens the effective prevention and treatment of infections.1 "The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs," said Shaun Rothwell, EVŌQ Nano CEO. While silver's antibacterial qualities have been known for centuries,2,3 it is widely established that the antimicrobial activity is due to ion emission, which poses toxicity risks for biomedical and consumer product applications.4-7 Realizing Silver's Therapeutic Potential Compared to traditional nanosilvers, EVQ-218 is differentiated due to its characterization and behavior as the first stable, nonemissive, pure silver nanoparticle that is on par with NIST standards for ideal materials, making it a superior candidate for biomedical and consumer product use.8 "Not only does EVQ-218 match NIST's standards for particle size and shape, but it possesses an ultrastable shell structure that completely inhibits ion emission — a first for a pure metal nanoparticle," said Bretni Kennon, Ph.D., principal investigator, EVŌQ Nano. Novel Mechanism of Action EVQ-218's antimicrobial efficacy is rooted in its ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This blocks activation of bacterial mutations that contribute to AMR. In contrast, nanosilvers with ions rupture cell walls, triggering activation of AMR pathways. Multi-Patented Laser Nanofabrication Process EVQ-218 is a high-energy produced silver nanoparticle with a method of manufacture that avoids chemical or biological synthesis. Ablation via a multiple, cross-laser system occurs at temperatures and pressures akin to diamond formation. The patented single-step, high-volume laser process generates stable, pure metal nanoparticles directly into pharmaceutical-grade water.8 The sub-10 nm spherical nanoparticles have an ultrastable shell structure that inhibits the hallmark ion emission that occurs in other nanosilver species.8 The resulting particle size and shape characteristics prevent the need for stabilizing chemistries.8 When factoring in shelf life, EVQ-218 maintains uniform stability for years; traditional nanosilvers degrade within weeks.8 These properties make EVQ-218 an attractive clean and green alternative to traditional nanosilvers.8 Advancing Antimicrobial Solutions With EVQ-218 To address the critical issue of healthcare-associated infections (HAIs), primarily caused by indwelling devices like catheters, EVŌQ Nano is collaborating with leading catheter manufacturers. By infusing EVQ-218 throughout the polymer, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.9 EVŌQ Nano has also received two grants from the Cystic Fibrosis Foundation for the development of an inhaled therapeutic to treat pulmonary bacterial infections. The company had its Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in March and, with the agency's feedback, is confidently advancing toward Phase I clinical trials. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates uniform, sub-10 nm nanoparticles with distinct surface chemistry. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Walsh TR, Gales AC, Laxminarayan R, Dodd PC. Antimicrobial resistance: addressing a global threat to humanity. PLoS Med. 2023 Jul 3;20(7):e1004264. doi: 10.1371/journal.pmed.1004264. PMID: 37399216; PMCID: PMC10317217. Alexander JW. History of the medical use of silver. Surg Infect. 2009;10(3):289. Medici S, Peana M, Nurchi VM, Zoroddu MA. Medical uses of silver—history, myths, and scientific evidence. J Med Chem. 2019;62:5923−5943. Stabryla LM, Johnston KA, Millstone JE, Gilbertson LM. Emerging investigator series: it's not all about the ion: support for particle-specific contributions to silver nanoparticle antimicrobial activity Environ Sci Nano. 2018;5:2047−2068. Kedziora A, Speruda M, Krzyzewska E, Rybka J, Bugla-Ploskonska G. Similarities and differences between silver ions and silver in nanoforms as antibacterial agents. Int J Mol Sci. 2018;19:444. Slavin YN, Asnis J, Häfeli UO, Bach H. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnology. 2017;15:65. Liao C, Li Y, Tjong SC. Bactericidal and cytotoxic properties of silver nanoparticles. Int J Mol Sci. 2019;20:449. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024;9(7):7891-7903. doi: 10.1021/acsomega.3c07745. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. . SOURCE EVOQ Nano

08 Apr 2024

·www.massdevice.com

Orthobond wins FDA de novo approval for antibacterial technology that could have vast device applications

The Monmouth Junction, New Jersey-based device developer says it’s the first time the FDA has granted a de novo request for a non-eluting coating designed to actively kill bacteria that could contaminate the surface of a medical device. Orthobond was founded by Princeton University Chemistry Professor Emeritus Jeffrey Schwartz and the late Dr. Gregory Lutz, who was physiatrist-in-chief emeritus at the Hospital for Special Surgery. Lutz died of cancer on March 5, but knew FDA approval was on the horizon. Orthobond CEO David Nichols called the FDA approval a “testament to Gregory’s legacy” in a statement shared with MassDevice. “We are proud to be able to carry it on into this next chapter.” The first application will be Ostaguard-treated SeaSpine Mariner pedicle screws, according to FDA records. Those could be used in patients early next year, Nichols (a former Zimmer Biomet executive) said in an exclusive interview with MassDevice. Orthobond’s proprietary technology is a quaternary ammonium compound coating that’s highly effective in neutralizing the different bacteria responsible for most device-related infections and can be applied to almost any device, he said. Medical Design & Outsourcing: How Orthobond’s antimicrobial coating prevents contamination of medical devices Unlike antibiotic-eluting devices, Ostaguard doesn’t use antibiotics so there’s no risk of creating drug-resistant superbugs. And while antimicrobial materials like silver, palladium and copper can kill bacteria, those toxic metals aren’t biocompatible with human tissue, Nichols said. “Those have been the barriers for decades,” he said. “[Ostaguard] is a brand new category for the FDA. It doesn’t come off the device — it is considered a device — and it actively kills bacteria.” The FDA gave the new category a generic name of “spinal fusion device with quaternary ammonium compound coating,” defined as “a rigid metallic implant device or system comprised of single or multiple components intended to facilitate fusion in skeletally mature patients. The device includes a quaternary ammonium compound coating that is covalently bonded to the device. Where applied, the coating is intended to reduce microbial contamination on the surface of the device prior to implantation. The device does not contain antimicrobial agents that act within or on the body and this device type does not include combination products.” According to an approval letter shared by Ostaguard, the FDA classified the product as a Class II device and established special controls, which Orthobond declined to divulge. While Orthobond said it found no evidence of local or systemic toxicity in sheep, guinea pig and canine testing, the coating technology has not been evaluated in human clinical trials. Orthobond says the technology’s intellectual property is protected through 2037 through three patent fences covering the covalent surface chemistry, antimicrobial layer and analytical processes, including 27 patents and 12 pending applications. Orthobond intends to seek 510(k) clearances for additional orthopedic spinal implant indications before expanding to other fields such as joint reconstruction, oncology, sports medicine, plastic surgery and cardiovascular. “We’re working on a neuromodulation device, there’s a trauma device we’re working on, and we’re going to work on a cochlear implant,” Nichols said. “If you use a cochlear implant and it gets infected, you pretty much lose your hearing. That’s something that they want to solve.” “We’d like to be as broad as possible,” he continued. “… This should be on all devices that get used. There’s no reason why not. If you’re going to sterile package them, why don’t you put an antibacterial on them?” Beyond medtech, Orthobond leaders believe the technology could also have commercial and industrial applications in areas such as automotive, consumer products and textiles. about how Orthobond’s Ostaguard antibacterial technology works and additional potential applications at our sister site, Medical Design & Outsourcing.

Drug Approval

22 Feb 2024

·www.prnewswire.com

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 Billion Catheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated infections (HAIs), which are some of the most common complications of hospital care. More than 1 million HAIs occur annually in the U.S., causing significant morbidity and mortality. The majority of HAIs are associated with indwelling devices, with catheter-associated urinary tract infections (CAUTIs) representing the most common type.1 Rising antimicrobial resistance has compounded this health threat — as up to one-third of CAUTIs in the U.S. are drug resistant,2 with annual treatment cost exceeding $13 billion.3 "For nearly 30 years, companies have tried to create antimicrobial devices, but the performance never proved effective. Our nanoparticle technology represents an exciting innovation that could profoundly reduce infections associated with medical devices like catheters without contributing to antibiotic resistance," said Shaun Rothwell, CEO of EVŌQ Nano. "With its proven ability to resist microbial growth and biofilm formation without triggering antimicrobial resistance, this platform has the potential to significantly impact device-related infections — much like the antibiotic revolution transformed infectious disease treatment a century ago." By infusing EVŌQ Nano's proprietary nanoparticle, EVQ-218, throughout the polymer itself, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.4 Strong Antimicrobial Efficacy In collaboration with the world's leading catheter manufacturers, extensive lab testing on catheters, luers, and fittings manufactured with EVŌQ Nano's EVQ-218 nanoparticle infused throughout the polymer, demonstrated: Strong antibacterial, antifungal, and antibiofilm efficacy Staphylococcus aureus: 7-8 log reduction Pseudomonas aeruginosa: 6-7.5 log reduction Candida albicans: 5-6.5 log reduction Broad-spectrum activity against 64 bacterial strains tested No degradation of antimicrobial activity; sustained presence for the life of the product Novel Mechanism of Action Existing antimicrobial solutions for medical devices have fallen short. Coatings slough off, degrade over time, and can only be applied to limited materials. While silver is a proven and powerful antimicrobial, current antibacterial catheters externally coated with silver lose efficacy once inserted due to natural sloughing of the material coupled with the short life of silver ions. This combination hinders the antimicrobial activity of current products. EVQ-218 is the first and only non-ionic silver nanoparticle. Extensive studies characterize EVQ-218 as a new form of silver nanoparticle (AgNP), manufactured with EVŌQ Nano's multi-patented nanofabrication process that requires only laser energy, ultrapure water, and pure silver metal.5 Unlike standard silver nanoparticles, EVQ-218 has true "bare" silver surface chemistry, with greater group stability that mitigates the need for added stabilizers.5 The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs. EVQ-218 delivers high antimicrobial efficacy without ion emissions.6,7 Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This avoids activation of bacterial mutations that contribute to antimicrobial resistance. In contrast, nanoparticles with silver ions rupture cell walls, triggering activation of resistance pathways. By incorporating antimicrobial protection into the material manufacturing process, EVŌQ Nano's technology enables the next generation of medical devices to more effectively guard against disease. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates nanoparticles that are uniformly sized, surfactant-free, with consistent spherical morphology, and no ion emissions under standard and stressed conditions. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Health Care-Associated Infections. Patient Safety Network. Published September 7, 2019. Accessed November 21, 2023. Werneburg GT. Catheter-associated urinary tract infections: current challenges and future prospects. Res Rep Urol. 2022; Apr 4;14:109-133. doi: 10.2147/RRU.S273663. PMID: 35402319; PMCID: PMC8992741 Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Agency for Healthcare Research and Quality. Content last reviewed November 2017. Accessed January 19, 2024. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024. doi: 10.1021/acsomega.3c07745 Niedermeyer W, inventor; ATTOSTAT Inc., assignee. Method and apparatus for production of uniformly sized nanoparticles. US patent 9,849,512. November 9, 2017. Dimpka CO, Calder A, Gajjar P, Merugu S, Huang W, Britt DW, McLean JE, Johnson WP, Anderson AJ. Interaction of silver nanoparticles with an environmentally beneficial bacterium, Pseudomonas chlororaphis. J. Haz. Mat. 2011; 188:428-435. doi: 10.1016/j.jhazmat.2011.01.118 SOURCE EVŌQ Nano

100 Deals associated with Silver Nitrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01730	-	D08AL01	DB11080

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Warts	AU	Sutherland Medical Pty Limited	26 Jul 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02519738 (CTgov)	Phase 3	Granuloma, Pyogenic	52	Silver Nitrate (Silver Nitrate)	hhzhctxgbu(wejcvpmcwd) = rnjisuwlfb jzvboqjsar (ukmxwfrcxh, zebldvcanm - nyutpiqqru) View more	-	25 Jan 2022
				Kenalog (Triamcinolone) (Kenalog (Triamcinolone))	hhzhctxgbu(wejcvpmcwd) = bcxhvubqej jzvboqjsar (ukmxwfrcxh, kamyantsuz - xjnafhjmtg) View more
NCT02116608 (CTgov)	Phase 4	Granuloma	26	Betadine	ocqggtvmgv(xfzhhgsvjm) = jmzosrjmal nofadjmrln (rppitibxam, utvwbpbxdh - qomajwpxhd) View more	-	13 Sep 2021
AACR2020	Not Applicable	Glioblastoma Multiforme	-	Silver nanoparticles	nhxvudikxs(sebqeddatt) = ipphgzfuza sdpgmqviof (pvlvatlyoq )	Positive	15 Aug 2020
				Silver nanoparticles + low-level He-Ne laser	nhxvudikxs(sebqeddatt) = jivaeqjjij sdpgmqviof (pvlvatlyoq )
ERS2016	Not Applicable	Emphysema	12	Silver Nitrate solution 0.5%	mychnpmwja(vdgbltnpjb) = ycbhpzkwrh ofqlgpepla (ceqrjagjxk ) View more	Positive	01 Sep 2016
Pubmed \| J Burn Care Res	Not Applicable	Burns	89	Silver-Based Burns Dressing	skcwauivqp(mbsprrsxeg) = tbeheojbkt jmxenywuli (iprlvspzsp )	-	01 Jan 2016
				Silver-Based Burns Dressing	skcwauivqp(mbsprrsxeg) = wqxttievck jmxenywuli (iprlvspzsp )
Pubmed \| J Am Coll Surg	Not Applicable	-	147	Total Occlusive Ionic Silver-Containing Dressing (Ionic silver-containing dressing)	pfipnrcszn(bkpizbnrio) = rpyvacmrzz stiwlhgend (ukecdrfyis )	Positive	01 Aug 2015
				Mupirocin ointment application	pfipnrcszn(bkpizbnrio) = caaxjzqkct stiwlhgend (ukecdrfyis )
NCT00675922 (Soaks, CTgov)	Phase 2/3	Burns	98	Sulfamylon (Percent Infections:Sulfamylon Site)	etgolafrxx(ioggimuiyg) = nnxlqgqfxo anuhrmredz (xlipfzgzyw, yljlknfeaa - cdvaqkunzs)	-	18 Jan 2013
				Silver Nitrate (Percent Infections: Silver Nitrate Site)	etgolafrxx(ioggimuiyg) = rjkkyhynwx anuhrmredz (xlipfzgzyw, wjxksmutqe - omfxagitqq)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis